JSAM
TEVA icon

J. Safra Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

J. Safra Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$651K Sell
19,204
-5,497
-22% -$183K 0.03% 155
2026
Q1 		$744K Sell
24,701
-623
-2% -$20K 0.04% 129
2025
Q4 		$790K Buy
25,324
+9,739
+62% +$240K 0.04% 123
2025
Q3 		$315K Buy
15,585
+33
+0.2% +$580 0.02% 144
2025
Q2 		$261K Buy
+15,552
New +$251K 0.02% 145

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

J. Safra Asset Management's TEVA Position: Q2 2026 in Review

J. Safra Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 22% in Q2 2026, selling an estimated $183K and leaving 19,204 shares worth $651K. The position accounts for 0.03% of the portfolio, ranked #155.

J. Safra Asset Management first reported a position in TEVA in Q2 2025 and has held it in 5 quarters since. The position peaked at $790K in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • J. Safra Asset Management held 19,204 shares of Teva Pharmaceuticals worth $651K as of Q2 2026.
  • J. Safra Asset Management sold 5,497 Teva Pharmaceuticals shares in Q2 2026, an estimated $183K.
  • Teva Pharmaceuticals made up 0.03% of J. Safra Asset Management's portfolio in Q2 2026, its #155 holding.
  • J. Safra Asset Management first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • J. Safra Asset Management's Teva Pharmaceuticals position peaked at $790K in Q4 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.